

# Sponsorship Duties and Responsibilities

Document No.:	POL002 v5.0
Author:	Lorn Mackenzie
Issue Date:	31 OCT 2024
Effective Date:	14 NOV 2024

## 1 Introduction

1.1 The Academic & Clinical Central Office for Research & Development (ACCORD) is a joint office comprising clinical research management staff from NHS Lothian (NHSL) and the University of Edinburgh (UoE).

1.2 ICH-GCP E6(R2) Guidelines and the Medicines for Human Use (Clinical Trials) Regulations (SI 2004 1031), as amended, specify that the sponsor of a clinical research study is:

*“An individual, company, institution, or organisation which takes responsibility for the initiation, management, and/or financing of a clinical trial”*

1.3 NHSL and the UoE assume the role of sponsor in a study where a qualified representative of the relevant institution formally consents to this role. This must be documented. NHSL and the UoE can assume the role of the sponsor as an individual institution or collectively i.e. co-sponsorship. NHSL responsibilities and duties towards studies that are hosted are defined in the UK Policy Framework for Health and Social Care Research.

## 2 Scope

2.1 This Policy is applicable to all researchers requesting Sponsorship approval for studies single/co-Sponsored by NHSL and/or UoE, or for studies co-sponsored by NHSL and a third party organisation e.g. another Higher Education Institute (HEI).

2.2 This Policy is also applicable to NHSL/UoE research governance staff involved with the oversight of studies, including performing Sponsorship review.

## 3 Policy

### 3.1 Responsibilities and Duties Retained

3.1.1 The following areas of sponsorship will not be transferred to another organisation and will be operationally undertaken by NHSL and the UoE, unless it is otherwise agreed and documented:

- *Quality assurance, including audit and vendor assessment* – procedures are described in ACCORD standard operating procedures (SOPs) under the “Quality Assurance” operational area.
- *Clinical trial monitoring, including source data verification* - procedures are described in ACCORD SOPs under the “Clinical Monitoring” operational area.
- *Record keeping (sponsor), including set up and maintenance of Trial Master Files (TMFs) and archiving* - procedures are described in ACCORD SOPs: “CR001 Establishing and Maintaining Trial Files – ISFs, TMFs and Sponsor Files and GS005 Archiving Essential Study Documentation.
- *The provision of indemnity/insurance*- procedures are described in ACCORD SOPs under the “Governance and Sponsorship” operational area.
- *Confirmation that appropriate finance is in place for the duration of a study* - procedures are described in ACCORD SOPs under the “Governance and Sponsorship” operational area.
- *Pharmacovigilance* - procedures are described in the ACCORD SOPs under the “Pharmacovigilance” operational area.

3.1.2 The following areas of sponsorship will not be transferred to another organisation by NHSL and UoE, unless it is otherwise agreed and documented. The following areas will be operationally performed by Investigators, or designees, in accordance with ACCORD procedures unless otherwise agreed and documented:

- *Protocol design* – procedures are described in ACCORD SOP: “CR007 Study Documents”.
- *Clinical study report preparation, including dissemination of results e.g. publication, registry reporting*- procedures are described in ACCORD SOP: “CR011 Research Study Reports & Publication of Results”.
- *Ethics and regulatory submissions and notifications*- procedures are described in ACCORD SOPs: “GS003 Sponsorship Approval” and “CR008 Preparing and Submitting Progress and Safety Reports”.
- *Record keeping (investigator), including set up and maintenance of Investigator Site Files (ISFs) and archiving* - procedures are described in ACCORD SOPs: “CR001 Establishing and Maintaining Trial Files – ISF, TMFs and Sponsor Files”, “CR009

Study Closure and Archiving” and other references can be found in the “Clinical Research” operational area SOPs where appropriate.

- 3.1.3 The wider conduct of clinical research by investigators is described in ACCORD SOPs under the “Clinical Research” operational area.

## **3.2 Responsibilities and Duties Delegated**

- 3.2.1 The following areas of sponsorship will be transferred to another organisation or the Chief Investigator (CI) and will be operationally undertaken by another organisation or the CI unless it is otherwise agreed and documented. It will be the responsibility of the sponsor or co-sponsors to ensure that the following responsibilities are formally transferred to another organisation or the CI in an agreement or equivalent document:

- *Statistical analysis* – all important details of study design and conduct and the principal features of its proposed statistical analysis must be clearly specified in a statistical analysis plan, or the study protocol, before the trial begins unless the sponsor or co-sponsors formally state otherwise. The sponsor or co-sponsors expect the responsible organisation/CI will ensure that statistical analysis is undertaken by appropriately qualified individuals. Study scope, context, design, conduct, data analysis techniques, safety/tolerability and reporting must all be considered in the preparation of a statistical analysis plan and the conduct of statistical analysis. ICH E9 Guidelines (Statistical Principles for Clinical Trials) must also be observed where applicable. The protocol and subsequent amendments pertaining to study design or methodology must be approved by the trial statistician.
- *Data capture and data management* - the sponsor or co-sponsors expect the responsible organisation/CI will utilise appropriately qualified individuals to design and implement data capture and data management systems in line with ICH-GCP E6(R2) guidelines, and the ACCORD Data Management Policy (POL012), unless the sponsor or co-sponsors formally state otherwise. When using electronic data systems, the organisation/CI must ensure that data processing systems conform to the requirements of the study, the ACCORD Computer Systems Validation Policy (POL007) and the ACCORD Computer System Validation Checklist referenced in ACCORD SOP “QA010 Use of Computerised Systems in Research”, where appropriate.
- *Data Monitoring*- the sponsor or co-sponsors expect the responsible organisation or Investigator to establish an independent data monitoring and safety committee (DMC) prior to study start-up for new CTIMPs unless the sponsor or co-sponsors formally state that a DMC is not required in accordance with risk

assessment. The DMC Charter will be prepared as per ACCORD SOP CR015 Data Monitoring Committee and Trial Steering Committee Charters. The DMC will assess the progress of the study, safety data, critical efficacy endpoints, any other relevant factors and make recommendations as to whether the study should continue, be modified, suspended or terminated. The DMC must operate according to written procedures and the proceedings and outcomes of meetings must be recorded.

- *Investigational Products* - the sponsor or co-sponsors expect the responsible organisation or CI to supply each Investigator with the Investigational Product, together with an Investigator's Brochure or equivalent, an Investigational Product dossier and written instructions for the handling and storage of the Investigational Product. The Investigational Product must be labelled and packaged according to EU Guidelines for Good Manufacturing Practice (GMP) – Medicinal Products for Human and Veterinary Use, Annex 13. Furthermore, the Investigational Product must be manufactured in accordance with GMP and regulatory requirements. In addition, the Investigational Product must be manufactured, packaged, labelled, coded, supplied and handled in accordance with the ACCORD SOP GS010 Sponsor Investigational Medicinal Product (IMP) Management, ICH-GCP E6(R2) guidelines, sections 5.12, 5.13 and 5.14.
- *Biological Sample Analysis* - the sponsor or co-sponsors expect the responsible organisation or Investigator to have systems in place to ensure that biological samples are stored, delivered to the site of analysis, analysed and destroyed in compliance with written study procedures. Biological specimens must be processed in accordance with the European Medicines Agency (EMA) Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples (2012).




## 4 References and Related Documents

- ICH-GCP E6(R2) Guidelines
- European Medicines Agency (EMA) Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples (2012)
- UK Policy Framework for Health and Social Care Research.
- EU Guidelines for Good Manufacturing Practice (GMP) – Medicinal Products for Human and Veterinary Use, Annex 13
- ICH E9 Guidelines (Statistical Principles for Clinical Trials)
- Framework Agreement between NHS Lothian and UoE in relation to R&D Activities

## 5 Document History

Version Number	Effective Date	Reason for Change
1.0	23 DEC 2010	Minor administrative changes
2.0	21 JUL 2016	New Policy template. References to new and revised SOPs added to text throughout (CR001, GS002, GS003, GS005 and PV001). Reference to EMA reflection paper for laboratories added to Sections 3.2.1 and 4.
3.0	25 JUL 2018	Update to the ICH-GCP E6 (R2), Guidelines and the UK Policy Framework for Health and Social Care Research. Revised SOPs added to text (CR015, GS010 and POL007). Minor administrative changes throughout.
4.0	22 SEP 2022	Change of author. Reference to new ACCORD Data Management Policy (POL012) added to section 3.2.
5.0	14 NOV 2024	Change of author. Reference to new ACCORD SOP QA010 Use of Computerised Systems in Research at section 3.2.1

## 6 Approvals

Sign	Date
 AUTHOR: Lorn Mackenzie, QA Manager, NHS Lothian, ACCORD	Oct 29, 2024
 <small>Fiona McArdle (Oct 29, 2024 14:40 GMT)</small> APPROVED: Fiona McArdle, Deputy R&D Director, NHS Lothian, ACCORD	Oct 29, 2024
 <small>Heather Charles (Oct 29, 2024 14:45 GMT)</small> AUTHORISED: Heather Charles, Head of Research Governance, NHS Lothian, ACCORD	Oct 29, 2024











# POL002 Sponsorship Duties and Responsibilities v5.0


Final Audit Report

2024-10-29


Created:	2024-10-29 (Greenwich Mean Time)
By:	Roisin Ellis (v1relli8@exseed.ed.ac.uk)
Status:	Signed
Transaction ID:	CBJCHBCAABAAMZAYHG3BgGOOpZglh9o1sFU7YUpUPefx

## "POL002 Sponsorship Duties and Responsibilities v5.0" History

-  Document created by Roisin Ellis (v1relli8@exseed.ed.ac.uk)  
2024-10-29 - 2:34:37 PM GMT- IP address: 62.253.82.233
-  Document emailed to fiona.mcardle@nhslothian.scot.nhs.uk for signature  
2024-10-29 - 2:37:47 PM GMT
-  Document emailed to heather.charles@nhslothian.scot.nhs.uk for signature  
2024-10-29 - 2:37:47 PM GMT
-  Document emailed to Lorn Mackenzie (lorn.mackenzie@nhslothian.scot.nhs.uk) for signature  
2024-10-29 - 2:37:47 PM GMT
-  Email viewed by fiona.mcardle@nhslothian.scot.nhs.uk  
2024-10-29 - 2:39:38 PM GMT- IP address: 52.102.18.5
-  Signer fiona.mcardle@nhslothian.scot.nhs.uk entered name at signing as Fiona McArdle  
2024-10-29 - 2:40:13 PM GMT- IP address: 62.253.82.231
-  Document e-signed by Fiona McArdle (fiona.mcardle@nhslothian.scot.nhs.uk)  
Signature Date: 2024-10-29 - 2:40:15 PM GMT - Time Source: server- IP address: 62.253.82.231
-  Email viewed by heather.charles@nhslothian.scot.nhs.uk  
2024-10-29 - 2:44:24 PM GMT- IP address: 52.102.17.69
-  Signer heather.charles@nhslothian.scot.nhs.uk entered name at signing as Heather Charles  
2024-10-29 - 2:45:56 PM GMT- IP address: 62.253.82.233
-  Document e-signed by Heather Charles (heather.charles@nhslothian.scot.nhs.uk)  
Signature Date: 2024-10-29 - 2:45:58 PM GMT - Time Source: server- IP address: 62.253.82.233

 Email viewed by Lorn Mackenzie (lorn.mackenzie@nhslothian.scot.nhs.uk)

2024-10-29 - 3:38:30 PM GMT- IP address: 52.102.18.5

 Document e-signed by Lorn Mackenzie (lorn.mackenzie@nhslothian.scot.nhs.uk)

Signature Date: 2024-10-29 - 3:38:42 PM GMT - Time Source: server- IP address: 192.41.114.229

 Agreement completed.

2024-10-29 - 3:38:42 PM GMT